Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
June 15 2020 - 8:01AM
Seelos Therapeutics, Inc. (SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced that it will host a key opinion leader (KOL) call to
provide updates regarding data from the Phase I study of SLS-002 on
Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also
provide an overview of the design for Seelos’ next study of SLS-002
for Acute Suicidal Ideation and Behavior (ASIB) in patients with
Major Depressive Disorder (MDD) during the call.
The call will feature a discussion with Michael E. Thase, MD,
professor of psychiatry at the University of Pittsburgh Medical
Center and the Western Psychiatric Institute and Clinic. Dr. Thase
is an active clinical investigator whose research focuses on mood
disorders and will be available to answer questions at the
conclusion of this call.
Raj Mehra, Ph.D., Chairman and CEO of Seelos Therapeutics, Inc.,
will also be on the call to answer any questions regarding the
Phase I data and the proposed trial design for Seelos’ lead
candidate, Intranasal Racemic Ketamine (SLS-002) for ASIB in
patients with MDD.
This call will be moderated by Mario Nacinovich, MSc, a member
of the adjunct faculty at Boston University. Mr. Nacinovich is the
founding editor of the Journal of Communication in Healthcare. He
is currently a show host on Reach MD and recently launched an
additional program on NRN, "Stealth on Health".
Dial-in and Webcast
InformationDomestic: 1-877-407-0789International: 1-201-689-8562Conference
ID: 13704973Webcast: Click Here for Webcast
Michael E. Thase, MD is a professor of psychiatry at the
University of Pittsburgh Medical Center and the Western Psychiatric
Institute and Clinic and obtained his medical degree at the Ohio
State University in 1979. He served as an intern, resident, and
fellow at the Western Psychiatric Institute and Clinic before
joining the University of Pittsburgh School of Medicine in 1983 as
an assistant professor of psychiatry. Since then, he has fulfilled
many roles at the University of Pittsburgh School of Medicine. Dr.
Thase has directed the Depression Treatment and Research Program at
Western Psychiatric Institute and Clinic since its inception in
1987 and is now the chief of adult academic psychiatry.
A fellow of the American Psychiatric Association, Dr. Thase has
received numerous honors in his field, including the Marie Eldredge
Award from the American Psychiatric Association. He is also a
member of many professional and scientific societies, including the
American Medical Association, the American College of
Neuropsychopharmacology, and the Society for Psychotherapy
Research. He has co-authored more than 340 scientific articles and
book chapters, as well as seven books. His published articles are
featured in various journals, including Archives of General
Psychiatry, the American Journal of Psychiatry, and
the British Journal of Psychiatry. He is the editor-in-chief
of Psychopharmacology Bulletin. A consultant and lecturer, Dr.
Thase remains active in the community by giving numerous
presentations at state hospitals. He also presents seminars for
community hospitals and the Office of Education and Regional
Programming.
About Seelos TherapeuticsSeelos Therapeutics,
Inc. is a clinical-stage biopharmaceutical company focused on the
development and advancement of novel therapeutics to address unmet
medical needs for the benefit of patients with central nervous
system (CNS) disorders and other rare diseases. The Company's
robust portfolio includes several late-stage clinical assets
targeting indications including Acute Suicidal Ideation and
Behavior (ASIB) in Major Depressive Disorder (MDD) or
Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome,
Parkinson’s Disease, other psychiatric and movement disorders plus
orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Forward Looking Statements
Statements made in this press release, which are not historical
in nature, constitute forward-looking statements for purposes of
the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. These statements include, among others, those
regarding the timing for the release of data from the Phase I study
of SLS-002 and the overview of the proposed design for Seelos’ next
study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in
patients with Major Depressive Disorder (MDD). These statements are
based on Seelos' current expectations and beliefs and are subject
to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. Risks associated to Seelos' business
include, but are not limited to, the risk of not successfully
executing its preclinical and clinical studies and not gaining
marketing approvals for its product candidates, the risks
associated with the implementation of a new business strategy, the
risks related to raising capital to fund its development plans and
ongoing operations, risks related to Seelos’ current stock price,
risks related to the global impact of COVID-19, as well as other
factors expressed in Seelos' periodic filings with the U.S.
Securities and Exchange Commission, including its Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q. Although we
believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations
will prove correct. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof, even if subsequently made available by us on our
website or otherwise. We do not undertake any obligation to update,
amend or clarify these forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities laws.
Contact Information:Anthony MarcianoHead of
Corporate CommunicationsSeelos Therapeutics, Inc. (SEEL)300 Park
Ave., 12th FlNew York, NY 10022(646)
293-2136anthony.marciano@seelostx.comhttps://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos
Seelos Therapeutics (NASDAQ:SEEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seelos Therapeutics (NASDAQ:SEEL)
Historical Stock Chart
From Apr 2023 to Apr 2024